Entera Bio Ltd. ENTX
Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.
Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2:
Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections can create a major treatment gap. From a technical standpoint, oral delivery of peptides and therapeutic proteins is challenging due to the enzymatic degradation within the gastrointestinal tract and poor absorption into the blood stream. We leverage our N-Tab® platform, which is designed to simultaneously stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.0K | $181.0K | $0 | $134.0K | $571.0K | $365.0K | $236.0K | $500.0K | — | — |
| Cost of revenue | $42.0K | $172.0K | $0 | $101.0K | $373.0K | $300.0K | — | — | — | — |
| Gross profit | $0 | $9.0K | $0 | $33.0K | $198.0K | $65.0K | — | — | — | — |
| R&D | $6.0M | $4.5M | $4.5M | $5.8M | $6.8M | $6.4M | — | — | — | — |
| SG&A | $398.0K | $340.0K | $4.4M | $7.3M | $5.7M | $4.9M | — | — | — | — |
| Total operating expenses | $11.5M | $9.6M | $8.9M | $13.1M | $12.4M | $11.2M | — | — | — | — |
| Operating income | -$11.5M | -$9.6M | -$8.9M | -$13.0M | -$12.2M | -$11.2M | -$11.5M | -$10.9M | -$11.3M | -$5.4M |
| Pre-tax income | -$11.4M | -$9.5M | -$8.9M | -$12.9M | -$12.2M | -$11.2M | — | — | — | — |
| Income tax | $0 | $14.0K | $29.0K | $137.0K | $59.0K | $20.0K | — | — | — | — |
| Net income | -$11.4M | -$9.5M | -$8.9M | -$13.1M | -$12.2M | -$11.2M | -$10.8M | -$10.3M | -$11.2M | -$1.2M |
| EPS, basic | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 | — | — | — | — | — |
| EPS, diluted | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 | 0.67 | — | — | — | — |
| Shares, diluted (wtd. avg.) | 46.2M | 37.7M | 29.0M | 28.8M | 26.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.1M | $8.7M | $11.1M | $12.4M | $25.0M | $8.7M | $15.2M | — | — | — |
| Receivables | $0 | $126.0K | $0 | $246.0K | $183.0K | $255.0K | — | — | — | — |
| Total current assets | $15.3M | $9.0M | $11.3M | $12.8M | $25.3M | $9.1M | — | — | — | — |
| Property, plant and equipment | $134.0K | $57.0K | $100.0K | $139.0K | $156.0K | $192.0K | — | — | — | — |
| Total assets | $16.0M | $9.4M | $11.8M | $13.1M | $26.0M | $9.7M | $16.7M | $13.3M | $13.3M | — |
| Accounts payable | $448.0K | $132.0K | $83.0K | $17.0K | $166.0K | $164.0K | — | — | — | — |
| Total current liabilities | $2.2M | $1.2M | $1.1M | $1.3M | $3.2M | $1.8M | — | — | — | — |
| Total liabilities | $2.9M | $1.3M | $1.4M | $1.4M | $3.4M | $2.2M | — | — | — | — |
| Retained earnings | -$125.4M | -$113.9M | -$104.4M | -$95.5M | -$82.4M | -$70.2M | — | — | — | — |
| Total equity | $13.1M | $8.1M | $10.4M | $11.8M | $22.6M | $7.5M | $13.8M | $10.1M | -$31.6M | -$25.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.4M | -$6.8M | -$7.3M | -$12.5M | -$9.1M | -$10.6M | — | — | — | — |
| Depreciation and amortisation | $30.0K | $46.0K | $56.0K | $64.0K | $53.0K | $63.0K | — | — | — | — |
| Stock-based compensation | $2.8M | $2.6M | $1.7M | $2.2M | $1.9M | $901.0K | — | — | — | — |
| Capital expenditure | $107.0K | $3.0K | $17.0K | $47.0K | $17.0K | $53.0K | — | — | — | — |
| Investing cash flow | -$107.0K | -$3.0K | -$17.0K | -$102.0K | -$17.0K | -$53.0K | — | — | — | — |
| Financing cash flow | $13.7M | $4.5M | $6.0M | $13.0K | $25.4M | $4.1M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-003077.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $500.0K | $236.0K | $365.0K | $571.0K | $134.0K | $0 | $181.0K | $42.0K |
| Gross profit | — | — | — | — | $65.0K | $198.0K | $33.0K | $0 | $9.0K | $0 |
| Net income | -$1.2M | -$11.2M | -$10.3M | -$10.8M | -$11.2M | -$12.2M | -$13.1M | -$8.9M | -$9.5M | -$11.4M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |